CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT

Bone Marrow Transplantation

Volumn 43, Issue 5, 2009, Pages 399-410

  Kapp, M ^a   Stevanovic S ^b   Fick, K ^a   Tan, S M ^a,c   Loeffler, J ^a   Opitz, A ^a   Tonn, T ^d   Stuhler, G ^a   Einsele, H ^a   Grigoleit, G U ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Hospital Ampang   (Malaysia)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CD8 ANTIGEN; CLADRIBINE; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; MUCIN 1; MYELOBLASTIN; THIOTEPA; TREOSULFAN; TUMOR ANTIGEN; WT1 PROTEIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOLOGICAL MONITORING; PRIORITY JOURNAL; TUMOR IMMUNITY;

EID: 62549149833     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.426     Document Type: Article

References (42)

1. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6 1018-1023.
2. + T-cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003; 102: 2892-2900.
3. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999; 93: 2336-2341.
4. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP et al. Cytotoxic T-cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998; 101: 2290-2296.
5. Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E et al Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes following allogeneic stem cell transplantation for acute lymphoblastic leukemia (ALL). Blood 2007; 110: 1924-1932.
6. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988; 263: 12820-12823.
7. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 1989; 43 1072-1076.
8. Brossart P, Schneider A, Dill P, Schammann T, Grunebach F, Wirths S et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 2001; 61: 6846-6850.
9. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccination with peptide-pulsed dendritic cells. Blood 2000; 96 3102-3108.
10. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanović S et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999; 93: 4309-4317.
11. Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW et al Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994; 91: 2105-2109.
12. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
13. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M et al. Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute: Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): Analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109: 3189-3197.
14. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20: 1295-1303.
15. Rammensee HG, Bachmann J, Emmerich NP, Bachor OA, Stevanovic' S. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-219.
16. Hebart H, Daginik S, Stevanović S, Grigoleit U, Dobler A, Baur M et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002; 99: 3830-3837.
17. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 1994; 179: 1109-1118.
18. + dendritic cells. Proc Natl Acad Sci USA 1996; 93: 2588-2592.
19. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase-3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132-2137.
20. Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA et al Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 1999; 163: 6867-6875.
21. Loeffler J, Swatoch P, Akhawi-Araghi D, Hebart H, Einsele H. Automated RNA extraction followed by rapid quantification of cytokine and chemokine gene expression using fluorescence resonance energy transfer. Clinical Chemistry 2003; 49: 985-988.
22. Nakamura R, Battiwalla M, Solomon S, Follmann D, Chakrabarti S, Cortez K et al. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biol Blood Marrow Transplant 2004; 10: 49-57.
23. Appelbaum FR. Hematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385-389.
24. Wu CJ, Ritz J. Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol 2006; 90: 133-173.
25. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217-223.
26. Ljungman P, de Witte T, Verdonck L, Gahrton G, Freycon F, Gravett P et al. Bone marrow transplantation for acute myeloblastic leukemia: an EBMT Leukemia Working Party prospective analysis from HLA-typing. Br J Haematol 1993; 84: 61-66.
27. Apperley JF, Jones L, Hale G, Waldmann H, Hows J, Rombos Y et al. Bone marrow transplantation for patients with chronic myeloid leukemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukemic relapse. Bone Marrow Transplant 1986; 1: 53-66.
28. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728.
29. Stevanović S. Identification of tumor-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2002; 2: 514-520.
30. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254 1643-1647.
31. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-327.
32. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332.
33. Scheibenbogen C, Sun Y, Keilholz U, Song M, Stevanović S, Asemissen AM et al. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T-cells from patients responding to IL-2-based treatment. Int J Cancer 2002; 98: 409-414.
34. Gückel B, Rentzsch C, Nastke MD, Marmé A, Gruber I, Stevanović S et al. Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers. J Cancer Res Clin Oncol 2006; 132: 265-274.
35. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885-13890.
36. Tsuboi A, Oka Y, Nakajima H, Fukuda Y, Elisseeva OA, Yoshihara S et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol 2007; 86: 414-417.
37. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J et al Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236-242.
38. Grigoleit GU, Kapp M, Hebart H, Fick K, Beck R, Jahn G et al. Dendritic cell Vaccination in allogeneic stem cell recipients: Induction of HCMV-speci.c CTL responses even in patients receiving a transplant from an HCMV-seronegative donor. J Inf Dis 2007; 196: 699-704.
39. den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL et al The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism. Science 1998; 279: 1054-1057.
40. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334: 281-285.
41. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B et al The human cytotoxic (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL. Journal of Virology 1996; 70: 7569-7579.
42. Walker BD, Flexner C, Birch-Limberger K, Fisher L, Paradis TJ, Aldovini A et al. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1989; 86: 9514-9518.